相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses
Laurel M. Schunselaar et al.
CLINICAL CANCER RESEARCH (2018)
Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition
Josine M. Quispel-Janssen et al.
CLINICAL CANCER RESEARCH (2018)
The recognition of ubiquitinated proteins by the proteasome
Guinevere L. Grice et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Prophylactic radiotherapy to prevent procedure-tract metastases
G. Zalcman et al.
LANCET ONCOLOGY (2016)
An evolutionarily conserved pathway controls proteasome homeostasis
Adrien Rousseau et al.
NATURE (2016)
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
Raphael Bueno et al.
NATURE GENETICS (2016)
Enhanced rate of degradation of basic proteins by 26S immunoproteasomes
Mary Raule et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)
PA28αβ Reduces Size and Increases Hydrophilicity of 20S Immunoproteasome Peptide Products
Mary Raule et al.
CHEMISTRY & BIOLOGY (2014)
Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition
Aurelien de Reynies et al.
CLINICAL CANCER RESEARCH (2014)
PA28αβ: The Enigmatic Magic Ring of the Proteasome?
Paolo Cascio
BIOMOLECULES (2014)
An immunoaffinity purification method for the proteomic analysis of ubiquitinated protein complexes
Petra Schwertman et al.
ANALYTICAL BIOCHEMISTRY (2013)
Molecular Basis of Differential Sensitivity of Myeloma Cells to Clinically Relevant Bolus Treatment with Bortezomib
Tamer B. Shabaneh et al.
PLOS ONE (2013)
What is the survival after surgery for localized malignant pleural mesothelioma?
Sandra M. Gelvez-Zapata et al.
INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY (2013)
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Alexei F. Kisselev et al.
CHEMISTRY & BIOLOGY (2012)
Molecular Pathways: Targeting Proteasomal Protein Degradation in Cancer
Susan M. Molineaux
CLINICAL CANCER RESEARCH (2012)
Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors
Simone Cenci et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma
Dean A. Fennell et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Vorinostat Eliminates Multicellular Resistance of Mesothelioma 3D Spheroids via Restoration of Noxa Expression
Dario Barbone et al.
PLOS ONE (2012)
Proteasome allostery as a population shift between interchanging conformers
Amy M. Ruschak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Biologic Impact of Proteasome Inhibition in Multiple Myeloma Cells-From the Aspects of Preclinical Studies
Teru Hideshima et al.
SEMINARS IN HEMATOLOGY (2012)
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew Bott et al.
NATURE GENETICS (2011)
The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance
D. Barbone et al.
CELL DEATH & DISEASE (2011)
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit
Christopher Blackburn et al.
BIOCHEMICAL JOURNAL (2010)
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines
Ying Wang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Transcription Factor Nrf1 Mediates the Proteasome Recovery Pathway after Proteasome Inhibition in Mammalian Cells
Senthil K. Radhakrishnan et al.
MOLECULAR CELL (2010)
Malignant pleural mesothelioma: Genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets
Oluf Dimitri Roe et al.
LUNG CANCER (2010)
Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules
Benoit Guillaume et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
Giada Bianchi et al.
BLOOD (2009)
Quantitative Proteomics Reveals the Function of Unconventional Ubiquitin Chains in Proteasomal Degradation
Ping Xu et al.
CELL (2009)
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo et al.
CELL (2009)
Malignant Pleural Mesothelioma
Anne S. Tsao et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Proteasome inhibitors in the treatment of multiple myeloma
J. J. Shah et al.
LEUKEMIA (2009)
Asbestos-induced lung diseases: an update
David W. Kamp
TRANSLATIONAL RESEARCH (2009)
Proteasome inhibitors in cancer therapy: Lessons from the first decade
Robert Z. Orlowski et al.
CLINICAL CANCER RESEARCH (2008)
Dampening Ab responses using proteasome inhibitors following in vivo B cell activation
Paolo Cascio et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids
Dario Barbone et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Proteasome Inhibitor MG132 Induces Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells
Bao-Zhu Yuan et al.
TRANSLATIONAL ONCOLOGY (2008)
Advances in the systemic therapy of malignant pleural mesothelioma
Dean A. Fennell et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma
Gavin J. Gordon et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Bortezomib inhibits nuclear factor-κB-dependent survival and has potent in vivo activity in mesothelioma
Andrea Sartore-Bianchi et al.
CLINICAL CANCER RESEARCH (2007)
Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors
A. C. Borczuk et al.
ONCOGENE (2007)
Global gene expression profiling of pleural mesotheliomas:: Overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction
F López-Ríos et al.
CANCER RESEARCH (2006)
Progressively impaired proteasomal capacity during terminal plasma cell differentiation
S Cenci et al.
EMBO JOURNAL (2006)
Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells
XJ Sun et al.
CANCER LETTERS (2006)
An overview of chemotherapy for mesothelioma
LM Krug
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2005)
Medical progress - Advances in malignant mesothelioma
BWS Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling
GJ Gordon et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The development of proteasome inhibitors as anticancer drugs
J Adams
CANCER CELL (2004)
Gene expression profiles predict survival and progression of pleural mesothelioma
HI Pass et al.
CLINICAL CANCER RESEARCH (2004)
Regulatory mechanisms controlling biogenesis of ubiquitin and the proteasome
MK London et al.
FEBS LETTERS (2004)
A proteasomal stress response: pre-treatment with proteasome inhibitors increases proteasome activity and reduces neuronal vulnerability to oxidative injury
CS Lee et al.
JOURNAL OF NEUROCHEMISTRY (2004)
The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites
AF Kisselev et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Proteasome inhibitors: from research tools to drug candidates
AF Kisselev et al.
CHEMISTRY & BIOLOGY (2001)
Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
U Schubert et al.
NATURE (2000)
分享论文
